Peripheral Vasodilator Drugs Global Market Report 2024

Peripheral vasodilator drugs are medications that primarily act on blood vessels outside of the heart and brain, specifically targeting the peripheral circulation. These drugs are used to widen (dilate) blood vessels, thereby reducing resistance to blood flow and lowering blood pressure.

The main types of peripheral vasodilator drugs include calcium channel blockers, direct-acting vasodilators, alpha-adrenergic blockers, potassium channel activators, nitrates, and others. Calcium channel blockers are medications that relax and widen blood vessels by preventing calcium from entering the cells of the heart and arterial walls, which helps reduce blood pressure and improve blood flow. These drugs are indicated for conditions such as hypertension, angina, heart failure, and others, and are used in settings such as hospitals and retail pharmacies.

The peripheral vasodilator drugs market research report is one of a series of new reports that provides peripheral vasodilator drugs market statistics, including peripheral vasodilator drugs industry global market size, regional shares, competitors with an peripheral vasodilator drugs market share, detailed peripheral vasodilator drugs market segments, market trends and opportunities, and any further data you may need to thrive in the peripheral vasodilator drugs industry. This peripheral vasodilator drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The peripheral vasodilator drugs market size has grown strongly in recent years. It will grow from $5.92 billion in 2023 to $6.27 billion in 2024 at a compound annual growth rate (CAGR) of 6%. The growth during the historic period can be attributed to the shift towards less invasive surgical techniques, increased demand for minimally invasive structural heart devices, ongoing training and education programs for healthcare professionals, rising healthcare expenditure, and a growing patient preference for non-surgical or minimally invasive treatment options.

The peripheral vasodilator drugs market size is expected to see strong growth in the next few years. It will grow to $7.97 billion in 2028 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to the increasing aging population, growing awareness about heart health, the implementation of screening programs, favorable reimbursement policies for structural heart procedures, and timely regulatory approvals for new structural heart devices. Major trends in the forecast period include increased collaboration, real-world evidence, gene therapy, preventive interventions, and value-based healthcare.

The increasing prevalence of cardiovascular diseases is expected to drive the growth of the peripheral vasodilator drug market. Cardiovascular diseases (CVDs) encompass a group of disorders affecting the heart and blood vessels, often caused by atherosclerosis, leading to conditions such as heart attacks, strokes, hypertension, and heart failure. The rise in CVD cases is primarily attributed to sedentary lifestyles, unhealthy diets, aging populations, increasing obesity rates, and related health conditions such as diabetes and hypertension. Peripheral vasodilators improve blood flow, reduce blood pressure, decrease the heart’s workload, and alleviate symptoms of conditions such as peripheral arterial disease. For instance, in January 2024, an article published by the American Heart Association, a US-based nonprofit organization focused on cardiovascular medical research, reported that cardiovascular disease caused 931,578 deaths in the US, slightly more than the 928,741 in 2020. Globally, there were 19.91 million CVD deaths in 2021, compared to 19.05 million in 2020. Therefore, the increase in the prevalence of cardiovascular diseases is driving the growth of the peripheral vasodilator drug market.

Major companies in the peripheral vasodilator drugs market are focusing on developing triple-drug combination therapies to optimize treatment outcomes and expand their market share in cardiovascular therapeutics. Triple-drug combination therapy is an antihypertensive fixed-dose combination (FDC) targeting patients who have not achieved adequate blood pressure control with dual-drug therapies or cannot tolerate diuretic-based combinations. For instance, in August 2023, Ajanta Pharma Limited, an India-based pharmaceutical company specializing in cardiology, introduced Met XL AMT, a novel triple-drug combination to manage hypertension among Indian patients. This FDC includes three antihypertensive agents, Telmisartan, Amlodipine, and Metoprolol. These agents work together to lower blood pressure by relaxing blood vessels, characteristic of peripheral vasodilators. The drug is specifically approved by DCGI for managing uncontrolled hypertension alongside stable coronary artery disease, making it the world's first FDC of metoprolol succinate (extended-release) 50 mg, amlodipine 5 mg, and telmisartan 40 mg.

In March 2022, Advent International Corporation, a US-based private equity investor, acquired the Mexico and Brazil pharmaceutical businesses from Perrigo Company plc for an undisclosed amount. This acquisition enhances Advent's regional investment strategy within the pharmaceutical sector, leveraging over two decades of industry experience to strengthen its market position. Perrigo Company plc is an Ireland-based pharmaceutical and health and wellness drug manufacturer that produces vasodilators such as nitroglycerin for hypertension.

Major companies operating in the peripheral vasodilator drugs market are Pfizer Inc., Bayer AG, Sanofi S.A., Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, Novartis AG, GSK plc, Takeda Pharmaceutical Company, Gilead Sciences Inc, Amgen Inc, Boehringer Ingelheim International GmbH, Merck & Co, Viatris Inc., Baxter, Teva Pharmaceutical Industries, Astellas Pharma, Daiichi Sankyo Company, Limited, Sun Pharmaceutical Industries, Mitsubishi Tanabe Pharma, Cipla Limited, Hikma Pharmaceuticals, Lupin Pharmaceuticals, Glenmark Pharmaceuticals Ltd, Torrent Pharmaceuticals, Ipca Laboratories, Alembic Pharmaceuticals.

North America was the largest region in the peripheral vasodilator drugs market in 2023. The regions covered in the peripheral vasodilator drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the peripheral vasodilator drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The peripheral vasodilator drugs market consists of sales of angiotensin II receptor blockers (ARBs), nitric oxide donors, direct renin inhibitors, and endothelin receptor antagonists. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.